Merck Animal Health Awards $50,000 in Scholarships to Five Next-Generation Swine Veterinarians
Merck Animal Health awarded $50,000 in scholarships to five veterinary students at the 57th American Association of Swine Veterinarians (AASV) Annual Meeting, held in Las Vegas, Nev.
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs
The United States Food and Drug Administration has approved NUMELVI™ (atinvicitinib tablets), a new treatment for itch associated with allergic dermatitis in dogs, developed by Merck Animal Health. The company says the medication is the first and only second-generation Janus kinase (JAK) inhibitor approved in the United States for this indication.
FDA Approves Exzolt Cattle-CA1 for Prevention and Treatment of New World Screwworm
On December 4, 2025, the U.S. Food and Drug Administration (FDA) granted conditional approval to Exzolt Cattle-CA1, a fluralaner topical solution from Merck Animal Health, for the use in beef cattle (≥ 2 months of age) and replacement dairy heifers (< 20 months of age). The approved uses include prevention and treatment of larval infestations by New World screwworm (NWS), and treatment and control of cattle fever tick.
The Feline Veterinary Medical Association and Merck Animal Health Champion Future Leaders in Feline Medicine
The Feline Veterinary Medical Association (FelineVMA) and Merck Animal Health are delighted to announce the 2025 Scholarships for Academic Excellence in Feline Healthcare recipients. This year’s recipients are Holly Kessler, The Ohio State University, Class of 2027, and Claire Stratton, Colorado State University, Class of 2026. Both recipients receive a $10,000 scholarship and a complimentary registration to the 2025 FelineVMA Annual Conference for their passion for feline medicine and a desire to elevate feline healthcare.
New Study Confirms Rapid Action of PROTAZIL® (1.56% diclazuril) Antiprotozoal Pellets for the Treatment of EPM
A new study shows PROTAZIL® (1.56% diclazuril) reaches effective levels in the cerebrospinal fluid within 12 hours, supporting its use in treating equine protozoal myeloencephalitis (EPM). Learn more about study findings and implications for horse owners.
MSD Animal Health Launches NUMELVI® (atinvicitinib) Tablets for Dogs – A Veterinary Innovation in Fast, Effective and Safe Targeted Itch Relief
MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Commission (EC) has approved NUMELVI™ (atinvicitinib) Tablets for Dogs.